APO RESEARCH · REPORT
Heart Failure Drugs
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
Product & engineering
Understand the product.
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
Selected research
Industry Research
Heart Failure Drugs Industry Research Report 2026
Market perspective
Heart failure occurs when your heart muscle doesn't pump blood as well as it should.
The market is concentrated as Novartis, Pfizer, AstraZeneca , Hikma, Teva etc. Turkey is the largest consumption place in the Turkey and Middle East & Africa market, with a consumption market share nearly 21%.
Report Scope
Read the full market overview
This report quantifies the global Heart Failure Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Heart Failure Drugs Market by Company
Novartis
Pfizer
AstraZeneca
Hikma
Teva
Cipla
Merck & Co.
Amgen
Roche
Sun Pharma
Mylan
Heart Failure Drugs Segment by Type
ACEI
Angiotensin II Receptor Blockers
ARNIs
Beta Blockers
Aldosterone Antagonists
Diuretics
Heart Failure Drugs Segment by Application
Reduced Ejection Fraction
Preserved Ejection Fraction
Heart Failure Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heart Failure Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Heart Failure Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Heart Failure Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Heart Failure Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ACEI
- Angiotensin II Receptor Blockers
- ARNIs
- Beta Blockers
- Aldosterone Antagonists
- Diuretics
Applications
- Reduced Ejection Fraction
- Preserved Ejection Fraction
Companies covered
- Novartis
- Pfizer
- AstraZeneca
- Hikma
- Teva
- Cipla
- Merck & Co.
- Amgen
- Roche
- Sun Pharma
- Mylan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Heart Failure Drugs Market Size (2021-2032)
- 2.2.2 Global Heart Failure Drugs Sales (2021-2032)
- 2.2.3 Global Heart Failure Drugs Market Average Price (2021-2032)
- 2.3 Heart Failure Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ACEI
- 2.3.3 Angiotensin II Receptor Blockers
- 2.3.4 ARNIs
- 2.3.5 Beta Blockers
- 2.3.6 Aldosterone Antagonists
- 2.3.7 Diuretics
- 2.4 Heart Failure Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Reduced Ejection Fraction
- 2.4.3 Preserved Ejection Fraction
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Heart Failure Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Heart Failure Drugs Sales (MT) of Manufacturers (2021-2026)
- 3.3 Global Heart Failure Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Heart Failure Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Heart Failure Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Heart Failure Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Heart Failure Drugs, Product Type & Application
- 3.8 Global Manufacturers of Heart Failure Drugs, Established Date
- 3.9 Global Heart Failure Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Heart Failure Drugs Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Heart Failure Drugs Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 AstraZeneca
- 4.3.1 AstraZeneca Company Information
- 4.3.2 AstraZeneca Business Overview
- 4.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
- 4.3.5 AstraZeneca Recent Developments
- 4.4 Hikma
- 4.4.1 Hikma Company Information
- 4.4.2 Hikma Business Overview
- 4.4.3 Hikma Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hikma Heart Failure Drugs Product Portfolio
- 4.4.5 Hikma Recent Developments
- 4.5 Teva
- 4.5.1 Teva Company Information
- 4.5.2 Teva Business Overview
- 4.5.3 Teva Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Teva Heart Failure Drugs Product Portfolio
- 4.5.5 Teva Recent Developments
- 4.6 Cipla
- 4.6.1 Cipla Company Information
- 4.6.2 Cipla Business Overview
- 4.6.3 Cipla Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cipla Heart Failure Drugs Product Portfolio
- 4.6.5 Cipla Recent Developments
- 4.7 Merck & Co.
- 4.7.1 Merck & Co. Company Information
- 4.7.2 Merck & Co. Business Overview
- 4.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
- 4.7.5 Merck & Co. Recent Developments
- 4.8 Amgen
- 4.8.1 Amgen Company Information
- 4.8.2 Amgen Business Overview
- 4.8.3 Amgen Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amgen Heart Failure Drugs Product Portfolio
- 4.8.5 Amgen Recent Developments
- 4.9 Roche
- 4.9.1 Roche Company Information
- 4.9.2 Roche Business Overview
- 4.9.3 Roche Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Roche Heart Failure Drugs Product Portfolio
- 4.9.5 Roche Recent Developments
- 4.10 Sun Pharma
- 4.10.1 Sun Pharma Company Information
- 4.10.2 Sun Pharma Business Overview
- 4.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
- 4.10.5 Sun Pharma Recent Developments
- 4.11 Mylan
- 4.11.1 Mylan Company Information
- 4.11.2 Mylan Business Overview
- 4.11.3 Mylan Heart Failure Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Mylan Heart Failure Drugs Product Portfolio
- 4.11.5 Mylan Recent Developments
5 Global Heart Failure Drugs Market Scenario by Region
- 5.1 Global Heart Failure Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Heart Failure Drugs Sales by Region: 2021-2032
- 5.2.1 Global Heart Failure Drugs Sales by Region: 2021-2026
- 5.2.2 Global Heart Failure Drugs Sales by Region: 2027-2032
- 5.3 Global Heart Failure Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Heart Failure Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Heart Failure Drugs Revenue by Region: 2027-2032
- 5.4 North America Heart Failure Drugs Market Facts & Figures by Country
- 5.4.1 North America Heart Failure Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Heart Failure Drugs Sales by Country (2021-2032)
- 5.4.3 North America Heart Failure Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Heart Failure Drugs Market Facts & Figures by Country
- 5.5.1 Europe Heart Failure Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Heart Failure Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Heart Failure Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Heart Failure Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Heart Failure Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Heart Failure Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Heart Failure Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Heart Failure Drugs Market Facts & Figures by Country
- 5.7.1 South America Heart Failure Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Heart Failure Drugs Sales by Country (2021-2032)
- 5.7.3 South America Heart Failure Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Heart Failure Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Heart Failure Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Heart Failure Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Heart Failure Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Heart Failure Drugs Sales by Type (2021-2032)
- 6.1.1 Global Heart Failure Drugs Sales by Type (2021-2032) & (MT)
- 6.1.2 Global Heart Failure Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Heart Failure Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Heart Failure Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Heart Failure Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Heart Failure Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Heart Failure Drugs Sales by Application (2021-2032)
- 7.1.1 Global Heart Failure Drugs Sales by Application (2021-2032) & (MT)
- 7.1.2 Global Heart Failure Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Heart Failure Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Heart Failure Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Heart Failure Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Heart Failure Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Heart Failure Drugs Value Chain Analysis
- 8.1.1 Heart Failure Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Heart Failure Drugs Production Mode & Process
- 8.2 Heart Failure Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Heart Failure Drugs Distributors
- 8.2.3 Heart Failure Drugs Customers
9 Global Heart Failure Drugs Analyzing Market Dynamics
- 9.1 Heart Failure Drugs Industry Trends
- 9.2 Heart Failure Drugs Industry Drivers
- 9.3 Heart Failure Drugs Industry Opportunities and Challenges
- 9.4 Heart Failure Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst